EPO and chronic kidney disease: The use of guideline-directed medical therapy for heart failure (HF) as well as erythropoietin-stimulating agents for the management of anemia in chronic kidney disease (CKD) has not been shown to be as effective in patients with CRAS as in isolated conditions (2, 6, 7).